Savara Inc. Common Stock (SVRA)
Stock · NASDAQ · Health Care
$4.46as of 10/16/2026
Price chart
Active signals
SVRA Signal Track Record
How signals performed across all stocks →What SVRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 50 | +4.2% | 56% | September 18, 2026 |
| Bollinger Band Breakout | 23 | +2.9% | 57% | June 18, 2026 |
| Bollinger Band BreakdownActive now | 18 | +2.6% | 67% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -2.4% | 36% | September 8, 2026 |
| Any 20-session window (baseline) | +0.8% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 70
- Website
- savarapharma.com/
Fundamentals
- 1-day range
- $4.44$4.77
- Market cap
- $1.19B
- P/E (trailing)
- —
- P/E (forward)
- -12.13
- EPS (trailing)
- $-0.58
- Dividend yield
- —
- Beta
- 0.28
- Avg. volume
- 1.90M
- Dividend pay date
- April 28, 2017
How Savara Inc. Common Stock Makes Money
Where the revenue actually goes — FY2020 annual results
Source: 10-K filed Mar 10, 2021 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Savara Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12benzinga · 10/7/2026
- JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12Benzinga · 10/7/2026
- BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On WednesdayBenzinga · 10/7/2026
Insider Activity
Insider Actions →- Braden C. Parker · September 24, 2026 · Tax Withholding29.3K @ $5.07
- Robert Matthew Lutz · July 15, 2026 · Grant70.0K
- Robert Matthew Lutz · July 15, 2026 · Grant35.0K
- David L. Lowrance · June 22, 2026 · Option Exercise87.7K @ $3.35
- David L. Lowrance · June 22, 2026 · Tax Withholding53.4K @ $5.5
- David L. Lowrance · June 22, 2026 · Tax Withholding10.1K @ $5.5
- David L. Lowrance · June 22, 2026 · Option Exercise12.5K @ $4.45
- David L. Lowrance · June 22, 2026 · Option Exercise218.8K @ $1.51
- David L. Lowrance · June 22, 2026 · Option Exercise56.9K @ $1.11
- David L. Lowrance · June 22, 2026 · Option Exercise129.3K @ $1.23
- David L. Lowrance · June 22, 2026 · Option Exercise75.0K @ $1.59
- David L. Lowrance · June 22, 2026 · Sale394.5K @ $5.68
- David L. Lowrance · June 22, 2026 · Tax Withholding60.1K @ $5.5
- David L. Lowrance · June 22, 2026 · Tax Withholding11.5K @ $5.5
- David L. Lowrance · June 22, 2026 · Tax Withholding28.9K @ $5.5
Institutional Ownership
March 31, 2026
- Total shares held
- 209.77M
- Total value held
- $1.14B
- Institutional holders
- 179
- Unknown24.47M
- Unknown17.60M
- Unknown13.74M
- Unknown13.57M
- Unknown12.36M
- Unknown11.29M
- Unknown9.72M
- Unknown9.54M
- Unknown7.78M
- Unknown7.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup
Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.